What is Affimed N.V. (AFMD) stock price today?

Affimed N.V. (AFMD) is currently trading at $0.18, up 0% today.

What is AFMD P/E ratio?

Affimed N.V.'s P/E ratio is -0.02. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is AFMD return on equity (ROE)?

Affimed N.V.'s return on equity (ROE) is -100.55%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Affimed N.V.'s market cap?

Affimed N.V. has a market capitalization of $2.98M.

NASDAQ · Biotechnology

Affimed N.V. (AFMD) Stock

$0.18 +0.00% NASDAQ: AFMD Healthcare

Valuation

Metric	Value
Price	$0.18
Market Cap	$2.98M
P/E Ratio	-0.02
P/B Ratio	0.04
P/S Ratio	0.31
EPS (TTM)	$-7.09
52-Week High	$8.95
52-Week Low	$0.02
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-100.55%
ROA	-109.04%
ROCE	-149.70%
Gross Margin	100.00%
Operating Margin	-1337.50%
Net Margin	-1325.00%
Debt/Equity	0.33
Current Ratio	3.25

Annual Financials (USD)

Metric	2019	2020	2021	2022	2023
Revenue	$21.0M	$28.0M	$40.0M	$41.0M	$8.0M
Operating Profit	$-32.0M	$-35.0M	$-64.0M	$-88.0M	$-107.0M
Net Profit	$-32.0M	$-41.0M	$-58.0M	$-86.0M	$-106.0M
EPS	$-5.04	$-4.96	$-4.81	$-6.04	$-7.09
Op Margin	-151.3%	-122.4%	-158.6%	-213.1%	-1289.0%

Balance Sheet (USD)

Metric	2019	2020	2021	2022	2023
Total Assets	$112.0M	$176.0M	$225.0M	$201.0M	$97.0M
Total Liabilities	$74.0M	$104.0M	$89.0M	$48.0M	$39.0M
Cash	$95.0M	$147.0M	$198.0M	$190.0M	$39.0M
Borrowings	$3.0M	$1.0M	$19.0M	$18.0M	$19.0M

Cash Flow (USD)

Metric	2019	2020	2021	2022	2023
Operating Cash Flow	$-29.0M	$-19.0M	$-87.0M	$-105.0M	$-110.0M
Investing Cash Flow	$3.0M	$8.0M	$-8.0M	$5.0M	$-40.0M
Financing Cash Flow	$-2.0M	$-2.0M	$-8.0M	$-6.0M	$0
Net Cash Flow	$0	$52.0M	$51.0M	$-7.0M	$-152.0M
Free Cash Flow	$-31.0M	$-20.0M	$-90.0M	$-106.0M	$-114.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.16
FCF Yield	-4375.37%
Quick Ratio	3.23
Interest Coverage	-59.06
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ARAVAravive, Inc.	$0.04	-13.39%	-0.02	$2.95M	0.00%
BCELAtreca, Inc.	$0.09	-1.32%	-0.04	$3.57M	0.00%
EIGRQEiger BioPharmaceuticals, Inc.	$8.50	+6.25%	-0.17	$12.59M	0.00%
GMDAGamida Cell Ltd.	$0.03	+0.00%	-0.08	$4.34M	0.00%
GRTSGritstone bio, Inc.	$0.03	-31.78%	-0.03	$3.80M	0.00%

About Affimed N.V.

Affimed N.V. operates as a clinical-stage biopharmaceutical enterprise, concentrating its efforts on the identification and advancement of innovative cancer immunotherapies across the United States, Germany, and the broader European region. A key asset in their development pipeline is AFM13. This candidate has successfully concluded its Phase II clinical study for peripheral T-cell lymphoma and is currently progressing through Phase IIa trials for CD30-positive lymphoma, alongside a Phase I trial for Hodgkin lymphoma. Beyond AFM13, Affimed is actively developing several other therapeutic candidates. These include AFM24, a distinctive tetravalent, bispecific innate cell engager designed to target both epidermal growth factor receptor (EGFR) and CD16A; it is presently undergoing Phase IIa clinical trials for a range of advanced cancers. Further back in the pipeline are AFM28, an innate cell engager (ICE) in preclinical development for acute myeloid leukemia, and AFM32, another ICE candidate also in preclinical stages, aimed at solid tumors. The company has forged strategic collaboration agreements with prominent institutions such as The University of Texas MD Anderson Cancer Center, Genentech, Inc., and Roivant Sciences Ltd. Moreover, it benefits from a research funding agreement with The Leukemia & Lymphoma Society. Founded in 2000 and headquartered in Heidelberg, Germany, the organization transitioned its name to Affimed N.V. in October 2014, having previously operated as Affimed Therapeutics B.V.

Affimed N.V. is headquartered in DE.

Affimed N.V. (AFMD) stock trades at $0.18 with a market capitalization of $2.98M. The stock is valued at a price-to-earnings (P/E) ratio of -0.02, price-to-book of 0.04, price-to-sales of 0.31. Over the past 52 weeks the stock has ranged between $0.02 and $8.95, and currently trades 98.0% below its 52-week high.

On profitability, Affimed N.V. generates a return on equity (ROE) of -100.55%, return on capital employed of -149.70%, an operating margin of -1337.50%, a net profit margin of -1325.00%.

Official website: www.affimed.com

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides